Everest Medicines Receives $280 Million from Gilead’s Immunomedics Following Partnership Cancellation
China-based Everest Medicines (HKG: 1952) has announced a significant financial development, receiving a full upfront...
Immunomedics
Everest Medicines Receives $280 Million from Gilead Sciences for Partnership Cancellation
China-based Everest Medicines (HKG: 1952) has announced that it has received a full upfront payment...